Apothecary Pharma LLC has announced a voluntary recall of compounded tirzepatide (a GLP-1–based injection) after sterility concerns were identified. The Los Angeles Times reports the recall covers 22 vials, citing a “lack of assurance of sterility” in the company’s notice.
Other coverage highlights the potential patient risks associated with compounded injectables when sterility is not assured, including possible infection if contamination occurs. Times of India also notes that compounded medicines are not the same as FDA-approved products and frames the recall as a precaution related to quality assurance. While the outlets agree on the underlying issue—sterility assurance—the emphasis differs: one focuses on the specific wording and scope of the recall, while the other broadens the discussion to explain why compounded injection quality controls matter and how patients should distinguish compounded products from FDA-approved alternatives.
